These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 19286392)

  • 41. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
    Mocciaro F; Orlando A; Scimeca D; Cottone M
    Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
    Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases.
    Uehara T; Kato K; Ohkusa T; Sugitani M; Ishii Y; Nemoto N; Moriyama M
    J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S62-6. PubMed ID: 20586868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The increased expression of an array of C-X-C and C-C chemokines in the colonic mucosa of patients with ulcerative colitis: regulation by corticosteroids.
    Yang SK; Choi MS; Kim OH; Myung SJ; Jung HY; Hong WS; Kim JH; Min YI
    Am J Gastroenterol; 2002 Jan; 97(1):126-32. PubMed ID: 11808935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
    J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study.
    Kaser A; Mairinger T; Vogel W; Tilg H
    Wien Klin Wochenschr; 2001 Dec; 113(23-24):930-3. PubMed ID: 11802508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa.
    Zwolinska-Wcislo M; Brzozowski T; Budak A; Kwiecien S; Sliwowski Z; Drozdowicz D; Trojanowska D; Rudnicka-Sosin L; Mach T; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2009 Mar; 60(1):107-18. PubMed ID: 19439813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use.
    Cui G; Olsen T; Christiansen I; Vonen B; Florholmen J; Goll R
    Scand J Clin Lab Invest; 2006; 66(3):249-59. PubMed ID: 16714253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.
    Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S
    Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis.
    Yamamoto T; Saniabadi AR; Maruyama Y; Umegae S; Matsumoto K
    Dig Liver Dis; 2007 Jul; 39(7):626-33. PubMed ID: 17532273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome following infliximab therapy in children with ulcerative colitis.
    Hyams JS; Lerer T; Griffiths A; Pfefferkorn M; Stephens M; Evans J; Otley A; Carvalho R; Mack D; Bousvaros A; Rosh J; Grossman A; Tomer G; Kay M; Crandall W; Oliva-Hemker M; Keljo D; LeLeiko N; Markowitz J;
    Am J Gastroenterol; 2010 Jun; 105(6):1430-6. PubMed ID: 20104217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis.
    Fanjiang G; Russell GH; Katz AJ
    J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):312-7. PubMed ID: 17325550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab in the treatment of severe ulcerative colitis: a follow-up study.
    Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
    Eur Rev Med Pharmacol Sci; 2004; 8(5):235-7. PubMed ID: 15638237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.